TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Investor Lawsuit Filed Against Directors

  • Investors who purchased shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and currently hold any of those NASDAQ: RARE shares have certain options and should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Company
Ultragenyx Pharmaceutical Inc.
Security
NASDAQ: RARE

Case Name
Ultragenyx Pharmaceutical Derivative Shareholder Case
Type of Lawsuit
Stockholder Derivative Action
You must register or login to receive notifications.

Click here to subscribe to Ultragenyx Pharmaceutical Inc..
Summary

An investor in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) filed a lawsuit against directors of Ultragenyx Pharmaceutical Inc over alleged excessive pay of certain directors.
The plaintiff alleges alleging that the board has breached its fiduciary duty and engaged in self-dealing, unjust enrichment and waste in approving a compensation plan that grossly overcompensates the seven nonemployee directors. The plaintiff claims that the company's board is being paid excessive salaries and that the compensation plan fails to take in account Ultragenyx Pharmaceutical’s revenue and continues to pay the directors more than twice what peers at similarly sized, publicly traded companies are paid

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Ultragenyx Pharmaceutical Inc. reported that its Net Loss increased from $245.87 million in 2016 to $302.13 million in 2017. Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) declined from $90.98 per share in September 2018 to as low as $46.40 per share on October 29, 2018.